{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:22:25Z","timestamp":1794867745726,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obesity remains a major global health challenge, driving type 2 diabetes, cardiovascular disease, and other complications. Despite effective lifestyle and surgical interventions, pharmacotherapy uptake has historically been limited. Injectable GLP-1 receptor agonists, including semaglutide and tirzepatide, have redefined expectations for medical obesity therapy, achieving 15\u201320% weight reductions in clinical trials. However, barriers such as injections, cost, and adherence limit their real-world use. In September 2025, two pivotal phase-3 trials of oral GLP-1 therapies were published. ATTAIN-1 evaluated orforglipron in 3,127 adults with obesity over 72 weeks, demonstrating a mean weight loss of 11.2%, \u2265\u200910% weight loss in 54.6%, and improvements in cardiometabolic parameters. OASIS-4 studied oral semaglutide 25\u00a0mg in 307 adults over 64 weeks, showing a mean weight loss of 13.6%, \u2265\u200910% weight loss in 63%, and favorable metabolic changes. Both agents exhibited gastrointestinal adverse events consistent with the GLP-1 class; additionally, orforglipron had five mild pancreatitis cases, while oral semaglutide reported mild dysesthesia. These results confirm that oral GLP-1 receptor agonists can produce clinically meaningful weight loss and metabolic benefits, expanding options beyond injectables. Real-world adoption will hinge on adherence, tolerability, long-term safety, patient preference, and payer coverage. Oral GLP-1 therapies represent a transformative step in obesity management, offering a convenient alternative that may broaden access and optimize individualized care.<\/jats:p>","DOI":"10.1186\/s40842-025-00245-5","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:57:05Z","timestamp":1759748225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["From needles to pills: oral GLP-1 therapy enters the obesity arena"],"prefix":"10.1186","volume":"11","author":[{"given":"Gaetano","family":"Santulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"245_CR1","doi-asserted-by":"crossref","unstructured":"Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025.","DOI":"10.1056\/NEJMoa2511774"},{"key":"245_CR2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, Shaji C, Rubino D, Garvey WT. Oral semaglutide at a dose of 25\u00a0mg in adults with overweight or obesity. N Engl J Med. 2025;393:1077\u201387.","journal-title":"N Engl J Med"},{"key":"245_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"245_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"245_CR5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958\u201371.","journal-title":"N Engl J Med"},{"key":"245_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7326\/ANNALS-24-02547","volume":"178","author":"D Dicker","year":"2025","unstructured":"Dicker D, Karpati T, Promislow S, Reges O. Implications of the European association for the study of obesity\u2019s new framework definition of obesity: prevalence and association with all-cause mortality. Ann Intern Med. 2025;178:1065\u201372.","journal-title":"Ann Intern Med"},{"key":"245_CR7","doi-asserted-by":"publisher","first-page":"e2521170","DOI":"10.1001\/jamanetworkopen.2025.21170","volume":"8","author":"E Munte","year":"2025","unstructured":"Munte E, Zhang X, Khurana A, Hartmann P. Prevalence of extremely severe obesity and metabolic dysfunction among US children and adolescents. JAMA Netw Open. 2025;8:e2521170.","journal-title":"JAMA Netw Open"},{"key":"245_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/eurjpc\/zwae279","volume":"32","author":"KC Koskinas","year":"2025","unstructured":"Koskinas KC, Van Craenenbroeck EM, Antoniades C, Bluher M, Gorter TM, Hanssen H, Marx N, McDonagh TA, Mingrone G, Rosengren A, Prescott EB. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur J Prev Cardiol. 2025;32:184\u2013220.","journal-title":"Eur J Prev Cardiol"},{"key":"245_CR9","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC202405210","volume":"177","author":"AH Gilden","year":"2024","unstructured":"Gilden AH, Catenacci VA, Taormina JM, Obesity. Ann Intern Med. 2024;177:ITC65\u201380.","journal-title":"Ann Intern Med"},{"key":"245_CR10","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/eurjpc\/zwae025","volume":"31","author":"A Welsh","year":"2024","unstructured":"Welsh A, Hammad M, Pina IL, Kulinski J. Obesity and cardiovascular health. Eur J Prev Cardiol. 2024;31:1026\u201335.","journal-title":"Eur J Prev Cardiol"},{"key":"245_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/00031348231220576","volume":"90","author":"JL Hsu","year":"2024","unstructured":"Hsu JL, Farrell TM. Updates in bariatric surgery. Am Surg. 2024;90:925\u201333.","journal-title":"Am Surg"},{"key":"245_CR12","first-page":"e17","volume":"386","author":"G Santulli","year":"2022","unstructured":"Santulli G. Tirzepatide versus semaglutide once weekly in type 2 diabetes. N Engl J Med. 2022;386:e17.","journal-title":"N Engl J Med"},{"key":"245_CR13","doi-asserted-by":"crossref","unstructured":"Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G. Tirzepatide: A systematic update. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms232314631"},{"key":"245_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","volume":"178","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials. Ann Intern Med. 2025;178:199\u2013217.","journal-title":"Ann Intern Med"},{"key":"245_CR15","doi-asserted-by":"publisher","first-page":"100127","DOI":"10.1016\/j.obpill.2024.100127","volume":"12","author":"W Ghusn","year":"2024","unstructured":"Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024;12:100127.","journal-title":"Obes Pillars"},{"key":"245_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","volume":"9","author":"RJ Jalleh","year":"2024","unstructured":"Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024;9:957\u201364.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"245_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s11095-022-03302-1","volume":"39","author":"MK Mahapatra","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review. Pharm Res. 2022;39:1233\u201348.","journal-title":"Pharm Res"},{"key":"245_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bph.15682","volume":"179","author":"A Kabahizi","year":"2022","unstructured":"Kabahizi A, Wallace B, Lieu L, Chau D, Dong Y, Hwang ES, Williams KW. Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics. Br J Pharmacol. 2022;179:600\u201324.","journal-title":"Br J Pharmacol"},{"key":"245_CR19","doi-asserted-by":"crossref","unstructured":"Barber TM, Kabisch S, Pfeiffer AFH, Weickert MO. Dietary and lifestyle strategies for obesity. Nutrients. 2024;16.","DOI":"10.3390\/nu16162714"},{"issue":"Suppl 2","key":"245_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/dom.16296","volume":"27","author":"I Idris","year":"2025","unstructured":"Idris I, Anyiam O. The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity. Diabetes Obes Metab. 2025;27(Suppl 2):20\u201334.","journal-title":"Diabetes Obes Metab"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00245-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:44:22Z","timestamp":1781613862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-025-00245-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00245-5","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"6 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Prof. Santulli is the Editor-in-Chief of Cardiovascular Diabetology - Endocrinology Reports.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}